Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 28, 2025 07:01 ET | Source: AbbVie Canada

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s...
November 26, 2025 07:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced...
November 25, 2025 09:30 ET | Source: AbbVie Canada

Lancement du Prix AbbVie des innovateurs en biotechnologies au Québec : AbbVie et adMare BioInnovations encouragent l’innovation dans le domaine des sciences de la vie

Le lancement d’un concours national, en collaboration avec adMare BioInnovations, illustre l’engagement d’AbbVie à favoriser le dynamisme de l’écosystème des biotechnologies au Québec.L’entreprise...
November 25, 2025 09:30 ET | Source: AbbVie Canada

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec One biotech will receive a year of laboratory and office...
November 25, 2025 09:15 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains on...
November 19, 2025 08:00 ET | Source: BioTech Breakthrough

PhaseV Receives BioTech Breakthrough Awards For “Analytics Solution of the Year”

LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...
November 19, 2025 06:30 ET | Source: Beacon Biosignals

Beacon Biosignals Announces Multi-Year Expansion of Strategic Collaboration with Takeda to Advance Narcolepsy Diagnosis and Neurobiomarker Discovery

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leading neurotechnology company powering AI-driven neurodiagnostics and precision medicines for the brain, today announced a multi-year...
November 13, 2025 06:30 ET | Source: Beacon Biosignals

Beacon Biosignals Raises $86M to Accelerate AI-Driven Insights into Brain Health

Beacon's 86$ million Series B funding will expand its precision medicine platform, unlocking treatments for neurological and psychiatric disease.
November 12, 2025 09:00 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204’s exceptional efficacy across multiple human cancer cell...
November 03, 2025 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Multiple Upcoming Investor Conferences in November

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening...